Journal of Atherosclerosis and Thrombosis
Online ISSN : 1880-3873
Print ISSN : 1340-3478
ISSN-L : 1340-3478
Original Articles
Clinical Efficacy and Safety of Rosuvastatin in Japanese Patients With Heterozygous Familial Hypercholesterolemia
Hiroshi MabuchiAtsushi NoharaToshinori HigashikataKosei UedaHideaki BujoTeruhiko MatsushimaYoshihiko IkedaMasahiro Nii
Author information

2004 Volume 11 Issue 3 Pages 152-158


Rosuvastatin is a new statin that has been shown to produce substantial dose-dependent reductions in low-density lipoprotein cholesterol (LDL-C) in Western and Japanese hypercholesterolemic patients. Rosuvastatin efficacy and safety were assessed in an open-label, dose-titration trial of 37 Japanese patients with heterozygous familial hypercholesterolemia. After an 8-week dietary lead-in period, patients received rosuvastatin on the following schedule: 10 mg/day during weeks 0−6; 20 mg/day during weeks 6−12, and 40 mg/day for weeks 12−18. Mean percentage reductions from baseline in LDL-C (49.2−56.7%), total cholesterol (39.4−45.4%), and non-high-density lipoprotein cholesterol (non-HDL-C) (46.7−54.3%) were highly significant at each dose (p < 0.0001). Similar significant reductions in triglycerides (18.2−25.0%; p < 0.006) and increases in HDL-C (9.6−13.6%; p < 0.005) were observed. Rosuvastatin was well tolerated. Two patients withdrew from the study because of adverse events unrelated to the study treatment. No patients had clinically significant elevations in liver transaminases. Two patients exhibited a single increase in creatine kinase (one unrelated to study treatment, the other possibly related) with no muscle symptoms. Rosuvastatin produced significant beneficial changes in all lipid parameters in Japanese patients with heterozygous familial hypercholesterolemia and was well tolerated.

Information related to the author

この記事はクリエイティブ・コモンズ [表示 - 非営利 - 継承 4.0 国際]ライセンスの下に提供されています。
Previous article Next article